ID | 1282 |
Name of the vaccine | SP306 (in Japan) |
Microbe | Bacteria |
Disease name | Pertussis (Whooping Cough) |
Name of bacteria | Bordetella pertussis |
Type of vaccine | Combination |
Nucleic acid content | DNA |
Age | 11 to 12 years |
Description of the vaccine | Tdap vaccine. |
Name of the manufacturer | Sanofi Pasteur, a Sanofi Company |
Name of the manufacturing country | Japan |
Year of manufacture | 2015 |
Clinical Phase status | Clinical - Phase 3 |
Bacterial strain | Gram-negative coccobacillus. |
Efficacy | NA |
Vaccine formulation | Suspension for injection |
Dosage | Single dose of 0.1 mL. |
Mechanism of action | Antitoxin concentrations greater than or equal to 0.1 IU/mL. |
Route of administration | Intramuscular |
Indications | NA |
Export | NA |
Approval | NA |
Adjuvant | NA |
Repurposing | For tetanus and diphtheria. |
Side effects of vaccine | NA |
Post vaccination | NA |
Dose type | Single dose |
Interspecies transfer | NA |
PubMed identifier | NA |
Clinical trial number | NCT02089347 |
Reference | NA |
Other name | NA |
Additional Links | NA
|